Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02191917 · ClinicalTrials.gov registry record
A Study of Respiratory Muscle Strength in Patients With Late-onset Pompe Disease (LOPD)
A clinical trial, sponsored by BioMarin Pharmaceutical.
- Terminated
- Registry status
- 8
- Enrollment target
NCT02191917: Clinical Trial study, sponsored by BioMarin Pharmaceutical.
NCT02191917 is a clinical trial that was terminated before completion, run by BioMarin Pharmaceutical. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02191917 was terminated before completion, sponsored by BioMarin Pharmaceutical.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
Study 701-201 is a study in patients with late-onset Pompe disease (LOPD). The study will test respiratory muscle strength initially and again after 24 weeks in subjects treated or not treated with BMN 701 .
Primary Outcome
Pulmonary measure of change in maximal inspiratory pressure (MIP)
Interventions
- PROCEDURE Respiratory muscle strength measurements by different techniques.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-10-21 |
| Est. Completion | 2016-06-22 |
Why NCT02191917 stopped before completion
NCT02191917 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Respiratory muscle strength measurements by different techniques. is the first listed.
NCT02191917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02191917 about?
NCT02191917 is a clinical study titled "A Study of Respiratory Muscle Strength in Patients With Late-onset Pompe Disease (LOPD)". Study 701-201 is a study in patients with late-onset Pompe disease (LOPD). The study will test respiratory muscle strength initially and again after 24 weeks in subjects treated or not treated with BMN 701 .
What is the current status of trial NCT02191917?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2014-10-21. Estimated completion is 2016-06-22.
What interventions are being tested in trial NCT02191917?
The interventions under investigation include: Respiratory muscle strength measurements by different techniques. (PROCEDURE).
Who is sponsoring clinical trial NCT02191917?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI